IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Trinity Biotech plc & Encourages Investors with ...
October 06 2016 - 6:59PM
Business Wire
Khang & Khang LLP (the “Firm”) announces that it is
investigating claims against Trinity Biotech plc (“Trinity” or the
“Company”) (Nasdaq: TRIB) concerning possible violations of federal
securities laws.
If you purchased shares of Trinity and want more information,
please contact Joon M. Khang, Esquire, of Khang & Khang, 18101
Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949)
419-3834, or by e-mail at joon@khanglaw.com.
The investigation concerns whether Trinity and certain of its
officers and/or directors violated Sections 10(b) and 20(a) of the
Securities Exchange Act of 1934. On October 4, 2016, the Company
announced that it will withdraw its 510(k) premarket notification
submission for the Meritas Troponin-I Test and Meritas
Point-of-Care Analyzer on the advice of the U.S. Food & Drug
Administration. The Company also stated that it would reduce
spending by nearly 85% and that it would close a Swedish facility,
eliminating 40 jobs. When this news was released to the public,
shares of Trinity declined in value.
If you have any questions concerning this notice or your rights,
please contact Joon M. Khang, a prominent litigator for almost two
decades, by telephone: (949) 419-3834, or by e-mail at
joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161006006541/en/
Khang & Khang LLPJoon M. Khang, Esq.Telephone:
949-419-3834Facsimile: 949-225-4474joon@khanglaw.com
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Apr 2024 to May 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From May 2023 to May 2024